Chapter 40 The third issue of ITG Generating Elements begins (click in, please read, it is very important!)
(Front row tip: Today is the most critical time, it depends on whether you can be recommended! New theme Creation is not easy, please help me! )
The sudden price reduction of AkaRx company caused quite a stir, but Zhang Yang just understood it briefly and fully devoted himself to "ITG human myelopoietin" as he arranged. in development.
Three days later, he walked into the clinical trial center with a clinical phase III trial plan for "ITG Human Myelopoietin".
The person who received him was Feng Gang, deputy director of the center.
"Zhang Yang, long time no see, I miss you very much."
After the previous clinical trial of "Qingshan Avatrombopag Tablets", Feng Gang and Zhang Yang had a better relationship.
"Director Feng, your words may cause ambiguity!"
"Haha!"
Feng Gang smiled and patted Zhang Yang on the shoulder, his eyes Then it fell on the document in Zhang Yang's hand.
"What's wrong? Are you here to submit your second phase clinical trial plan for 'ITG Generator' again today?"
Zhang Yang shook his head:
"You are such a noble person who forgets things. We have passed the second clinical phase.”
“This is our latest clinical phase three design plan for ‘ITG Generator’, which has been modified in several places, so we have resubmitted it specially.”
< br>“Oh~”
Feng Gang deliberately lengthened his voice, with a smile on his lips.
Of course he knows that Qingshan Pharmaceutical’s “ITG Human Myelopoietin” has passed the second phase of trials, and it was revised five times in a row before it finally passed!
The reason why I ask this is because the previous "Qingshan Avatrombopag" tablets were so weird. The drug ingredients, dosage, and all parameters were not modified even once!
Now this "ITG human myelopoietin" is finally normal. After modifying the drug ingredients five times in a row, it finally completed the second phase of the trial.
That’s right!
This is the normal innovative drug research and development process!
"Okay, let me take a look and see what you have modified."
Zhang Yang handed over the Phase III clinical design plan without revealing his expression, but the next second, Feng Gang suddenly stood up, his face full of disbelief!
"This...Zhang Yang, what are you doing?!"
"The positioning of the drug has been changed, and the ultimate therapeutic effect has also been changed?!"
< br>
"If I remember correctly, in your previous clinical phase II design plan, 'ITG human myelopoietin' was designed as an auxiliary treatment drug. Now... you told me that you want to change it to a first-line drug?!"
< br>“Moreover!”
“Look at what you wrote about the effect of treatment!”
“We must achieve more than 95% cure of ‘aplastic anemia’!”
< br>"Cure, not treatment!"
Zhang Yang didn't speak, just nodded and smiled slightly.
“You are simply crazy!”
Feng Gang was furious, but the next second he suddenly thought of the recent rumors about the fierce competition between Qingshan Pharmaceutical and AkaRx Company, and he hurriedly and deeply thought about it. Take a breath and adjust your emotions.
"Zhang Yang, I know you are under a lot of pressure, but don't be so stressed out yet."
"Have you ever thought about when this 'ITG Human Myelopoietin' will be modified by you like this? In order to achieve the designed therapeutic effect, when can it pass the third clinical phase? ”
Zhang Yang breathed out gently, and he could hear the concern in Feng Gang's words.
But...
What Feng Gang didn't know was that "ITG human myelopoietin" was not an auxiliary treatment drug from the beginning. From the beginning, it was able to truly and completely cure "regeneration" A special medicine for "obstructive anemia"!
The previous clinical phase II was revised five times. This was just my own way to deceive others!
Now that the time is ripe, it is also time for "ITG Human Myelopoietin" to show its due effect!
"Director Feng, I know you care about me, but I'm very confident. Just submit it for approval." Seeing Zhang Yang's confident look, Director Feng was completely shocked.
After a while, he looked at the latest clinical phase III plan of "ITG Generator" on the table, and thought of the previous clinical trial of "Qingshan Avatrombopag Tablets" The plan suddenly came to mind.
Oh my god.
I originally thought this was a normal drug, but I didn’t expect it to be even more evil than “Qingshan Afa”!
……
The change in the clinical phase III design plan of “ITG Human Myelopoietin” was quickly approved.
After approval, it also means that "ITG human myelopoietin" can officially conduct Phase III clinical trials.
However.
When the approved clinical phase III plan was transferred to the Department of Hematology, Director Hu immediately noticed the abnormality of "ITG human myelopoietin"!
As the director of the Department of Hematology, he naturally needs to have a general understanding of these new drugs undergoing clinical trials in the department.
"What does this Feng Gang do? How could Tsingshan Pharmaceutical allow him to submit such an obviously wrong design plan?"
"To achieve more than 95% cure for aplastic aplastic disease Anemia' effect? ”
< br>“And the indications include mild aplastic anemia, common aplastic anemia and super-severe aplastic anemia, which means that all types of aplastic anemia can be cured regardless of type!”
“This is a normal design plan. What pharmaceutical company dares to design this? ”
"Does Feng Gang understand the difficulty of curing aplastic anemia?"
Director Hu was very angry.
You must know that in clinical trial plans, the most important assessment is "effective treatment effect"!
So,
In order to improve the effective therapeutic effect of drugs, major pharmaceutical companies often impose restrictions on indications when designing clinical programs, so that new drugs can only treat a certain type of disease more accurately. disease patients.
For example, when a targeted drug is used to treat lung cancer, during clinical trials, not only will it be explicitly required to enroll only patients with the corresponding target, but also whether they have a history of chemotherapy, radiotherapy, and whether they have been treated with other targeted drugs. Details such as experience and whether there are other medical conditions are strictly limited.
In short, the purpose is to eliminate interference and achieve the ideal treatment rate, thereby speeding up the time to market!
And now,
What did Feng Gang do!
Forget about the mild disease, it turned out to be a super severe aplastic anemia, and the whole system should be cured!
Is this possible? !
Thinking of this, he hurriedly took out his phone to call Feng Gang, but as soon as he took it out, he suddenly thought of Zhang Yang and another possibility.
Is it possible that this is Zhang Yang’s modified plan?
Hiss!
Director Hu suddenly became excited, his heart was pounding, and his original angry mood was suddenly replaced by excitement.
He didn't bother to contact Feng Gang and hurriedly found Zhang Yang's phone number.
As soon as he was connected, he asked urgently:
"Zhang Yang, I just saw the latest clinical phase III trial plan of your 'ITG human myelopoietin', in which the treatment effect was changed to Completely cured!”
“Did you change it yourself?”
Since Director Hu signed the request with the department doctor, Zhang Yang has always remembered Director Hu’s kindness.
After a moment of silence, he said:
"Yes, I changed it, I'm sure of it!"
"Okay, okay, okay!"
Hu The director said three times in a row, and then took a deep breath:
"I believe you, and I will immediately arrange for doctors from the general department to fully support your clinical phase III!"
Half an hour later, the clinical phase III recruitment materials for "ITG Human Myelopoietin" appeared in a conspicuous place in the inpatient department!
After a while, the whole department suddenly exploded!
PS: Thanks to book friend 202312223201520650 for the 100 coins.
Thank you to CCD7057 for 1 monthly ticket, thank you to the great evil and great good for 2 monthly tickets
(End of this chapter)